SCHEMBL2983304

SCHEMBL2983304

CSc1ncccc1Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18059729 0.77 L3MBTL1 (0.36)
SCHEMBL4257786 0.77 SMN1; SMN2 (0.44)
SCHEMBL5700020 0.77 ALOX5AP (0.38)
SCHEMBL5640712 0.74
SCHEMBL10833630 0.74 L3MBTL1 (0.47)
SCHEMBL24645057 0.73
SCHEMBL4987729 0.73
SCHEMBL3168798 0.73
SCHEMBL2140617 0.73
SCHEMBL18716442 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719394-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2026-04-08 EP disclosed
US-20260048051-A1 TREATMENT OF INFLAMMATORY BOWEL DISEASE ATOMWISE INC (US) 2026-02-19 US disclosed
US-12358904-B2 Inhibitors of TYK2 Atomwise Inc. (US) 2025-07-15 US disclosed
US-20240425484-A1 INHIBITORS OF TYK2 Atomwise Inc. 2024-12-26 US disclosed
US-20240417396-A1 INHIBITORS OF TYK2 Atomwise Inc. 2024-12-19 US disclosed
WO-2024250010-A2 INHIBITORS OF TYK2 Atomwise Inc. (US) 2024-12-05 WO disclosed
WO-2023146512-A1 COMPOUNDS AND METHODS OF USE THEREOF VIVACE THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
US-10844013-B2 Phenyl amino piperidine mTORC inhibitors and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2020-11-24 US disclosed
US-20200207716-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2020-07-02 US disclosed
EP-3538091-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF Navitor Pharmaceuticals, Inc. (US) 2019-09-18 EP disclosed
WO-2012116242-A1 THIAZOLE AND OXOZOLE CARBENE METAL COMPLEXES AS PHOSPHORESCENT OLED MATERIALS UNIVERSAL DISPLAY CORPORATION (US) 2012-08-30 WO disclosed
US-20120212126-A1 THIOAZOLE AND OXAZOLE CARBENE METAL COMPLEXES AS PHOSPHORESCENT OLED MATERIALS UNIVERSAL DISPLAY CORPORATION (US) 2012-08-23 US disclosed
US-20120212126-A1 THIOAZOLE AND OXAZOLE CARBENE METAL COMPLEXES AS PHOSPHORESCENT OLED MATERIALS UNIVERSAL DISPLAY CORPORATION (US) 2012-08-23 US disclosed
CN-102639500-A Tricyclic compound, preparation method and pharmaceutical use thereof SHANGHAI HENGRUI PHARM CO LTD 2012-08-15 CN disclosed
US-20100227889-A1 Benzimidazole Derivatives NOVARTIS AG (CH) 2010-09-09 US disclosed
US-20100227889-A1 Benzimidazole Derivatives NOVARTIS AG (CH) 2010-09-09 US disclosed
US-20100227889-A1 Benzimidazole Derivatives NOVARTIS AG (CH) 2010-09-09 US disclosed
EP-2004629-A2 BENZIMIDAZOLE DERIVATIVES Novartis AG (CH) 2008-12-24 EP disclosed
WO-2007112913-A2 BENZIMIDAZOLE DERIVATIVES NOVARTIS AG (CH) 2007-10-11 WO disclosed
WO-2007112913-A2 BENZIMIDAZOLE DERIVATIVES NOVARTIS AG (CH) 2007-10-11 WO disclosed